A research study, centered on magic mushrooms in Canada, reveals that nearly 80% of participants believe psilocybin, a compound found in magic mushrooms, should be an available medical treatment for patients in distress. Additionally, about two-thirds of these Canadian participants agreed that psilocybin should be legally accessible for those who require it.
Beyond simply advocating for its availability, an impressive 84.8 percent of participants think that the public health system should bear the costs of such therapies. A majority of Canadians perceive psilocybin as a feasible solution, especially for treating end-of-life distress.
[toc]
Key Takeaways:
- Residents of Québec, Ontario, Alberta, and British Columbia view psilocybin as a legitimate medical option to address end-of-life existential distress.
- Magic mushrooms are regarded as safe for treating existential distress.
- In two double-blind trials, participants reported immediate and long-lasting benefits, with effects persisting six months or more.
Understanding Existential Distress
Existential distress, akin to existential suffering, spiritual distress, and demoralization, arises when individuals grapple with their mortality. Patients may experience feelings of helplessness, isolation, anxiety, and a loss of purpose and meaning. This distress is especially prevalent in patients with life-threatening illnesses, potentially leading to thoughts of hastening death or suicide.
Mostly, individuals grappling with terminal illnesses or significant life changes are the ones who frequently experience this kind of distress. It profoundly impacts their mental health and overall quality of life.
Existential therapy aims to resolve issues like anxiety, depression, grief, loneliness, apathy, despair, identity confusion, feelings of purposelessness, and existential fear. It may necessitate multiple sessions and might not prove effective for everyone.
The doubt regarding the efficacy of such therapy is a major reason why many individuals opt for alternative treatments.
Health Canada’s Stance on Psilocybin for Treatment
Over the last two decades, preliminary clinical trials have highlighted the potential merits of psychedelic substances in managing complex mental disorders. Specifically, Psilocybin has demonstrated swift and long-lasting relief from existential distress in patients nearing life’s end.
Recognizing the potential efficacy of these suggested hallucinogenic mushrooms, especially when conventional treatments fail, Health Canada revised the Special Access Program in 2022. This revision enables healthcare providers to request controlled substances for their patients.
Canadians’ Advocacy for Psilocybin Access
A research published in the Palliative Care Journal examines societal views on psilocybin-assisted therapy for end-of-life care. The study’s data comprises:
| Methodology | Input from 2,800 Canadians from Québec, Ontario, Alberta, and British Columbia, 19% of whom had previously used psilocybin (15% in Québec, 26% in British Columbia). |
| Findings | 79.3% deem psilocybin-assisted therapy a legitimate medical option for treating end-of-life existential distress. 63.3% agree that psilocybin should be integrated into medical treatment. 84.8% endorse the delivery of this therapy by the public health system. 44.2% believe healthcare professionals should administer the substance without Health Canada’s supervision. |
These findings align with surveys from Canada, England, and Australia. The researchers underlined the uniqueness of their study as it focuses on the use of psychoactive substances to alleviate existential distress in end-of-life situations.
Reasons Behind Canadian Support for Psilocybin Use
An increasing number of Canadians are advocating the use of psilocybin for treatment, primarily due to insights from renowned research institutions. Another influential factor is the perceived safety of psilocybin mushrooms in relieving existential distress. Subjects across multiple studies have not reported severe negative health consequences, such as multi-organ failure.
| Study | Approach | Outcomes |
| Johns Hopkins Study | 51 patients received a high dose of psilocybin and a low dose as an active placebo control | Immediate and long-lasting |
| The benefits of the therapy can last up to six months or even longer. The success of this treatment is primarily due to mystical experiences that evoke a sense of unity and deep emotional revelations. | ||
| Trial at New York University | 29 patients were chosen at random to either receive psilocybin or the active placebo, niacin. | The results of this study were in line with those from Johns Hopkins. Participants who received psilocybin reported psychological relief and a renewed outlook on life and death. |
| BMC Palliative Care | The study involved interviewing nineteen participants, including 7 doctors, 4 nurses, 4 chaplains, 3 social workers, and a psychologist. The aim of the study was to gain insights into how professionals in palliative care perceive existential distress and their opinions on psychedelic therapy as a potential treatment. | Palliative care professionals expressed that psychedelic-assisted therapy (PAT) could potentially alleviate existential distress. |
Patient Experiences
Beyond scientific studies, there is further evidence supporting the effectiveness of psilocybin from various patient accounts. These stories highlight its potential to improve mental wellbeing and overall quality of life.
The Journey of Yokoi
Mio Yokoi, a patient with terminal stage 4 pancreatic cancer, shares her transformative experience during her therapy. She envisions herself on a raft, surrounded by nature and whimsical creatures. This vision bestows upon her a profound realization of the universe’s interconnectivity and support, providing her with immense peace and affirmation.
Despite receiving conventional mental health support, Yokoi still experienced severe anxiety and distress post-diagnosis. Psilocybin therapy enabled her to reconnect with her body and provided a tangible sense of love and support. This significantly improved her mental and emotional health.
The Story of Chrissy
Chrissy, a woman in her 50s, was diagnosed with stage 4 breast cancer, which had metastasized to her lungs. During the study, she was working full-time as an administrative supervisor in healthcare and identified as an atheist. She was diagnosed with Generalized Anxiety Disorder during her screening.
Chrissy experienced significant reductions in her anxiety, depression, fear of death, hopelessness, and demoralization levels. When asked whether her religious or spiritual beliefs had changed since her therapy session, she responded that the experiences had brought a sense of reality and significance to her beliefs.
Brenda’s Journey
Brenda, a woman in her sixties, was diagnosed with stage I colon cancer. During her screening process, it was discovered that she has never used hallucinogens. Moreover, she qualified for the diagnosis of Chronic Adjustment Disorder with accompanying Anxiety.
In her therapy sessions, Brenda experienced the sensation of dying on two occasions. Following these experiences, she no longer feared death, perceiving it as a natural part of life’s journey. She credited the study as the catalyst for her therapeutic process against childhood trauma. The data collected during her therapy reflected this significant transformation. It was observed that Brenda experienced reduced anxiety and fear of death, coupled with an increase in her spirituality.
Availability of Magic Mushroom Products in Canada
At the moment, there might be limitations in the availability of psilocybin capsules and other related products designed to alleviate existential distress or other mental health conditions. However, reliable online dispensaries can provide these products when needed.
| Properties | Brazilian Psilocybe Cubensis | Cambodian Psilocybe Cubensis | Melmac Psilocybe Cubensis |
| Origin | Native to Brazil and some adjacent South American countries. | Discovered in Cambodia, around the Angkor Wat Temple. | Descendant of Penis Envy mushrooms, which became popular in the 1970s. |
| Potency | Moderately potent; suitable for beginners. | Comparable in potency; ideal for those new to psilocybin. | Highly potent; recommended for individuals with intermediate to advanced experience. |
| Effects | Provokes mental stimulation, slight disorientation, enhanced color perception, euphoria, spiritual experiences, increased creativity, and improved concentration. | Induces an energizing and long-lasting high, subtle visual alterations, heightened creativity, euphoria, a gentle physical high, fractal visions, and feelings of joy. | Initiates profound shamanic experiences, vision quests, intense mystical experiences, enhanced creativity, focus, social awareness, and mood improvement. |
Ease End-of-life Distress with Psilocybin Products
Existential or end-of-life distress can significantly impact patients nearing the end of their lives. Conventional treatments for this distress can sometimes be insufficient, leading to an increase in Canadian advocacy for broader access to magic mushrooms in public healthcare. This growing public interest could potentially
We urge governing bodies to recognize the potential of magic mushrooms as a viable treatment option. Procure your psychedelics and avail our shroom delivery service at Magic Mushrooms Ottawa Canada.
Frequently Asked Questions
What should patients expect from Psilocybin-Assisted Therapy?
Each patient’s experience with Psychedelic-assisted therapy (PAT) can differ significantly. Therefore, proper preparation and adherence to specific procedures are crucial to ensure a positive outcome. Patients must go through comprehensive screening and mental readiness training before ingesting the substance.
- Session Preparation: Prior to the session, patients undergo a detailed assessment. The therapist engages the patient in a dialogue about their goals and expectations to form intentions for the session. The therapist also advises the patient about the potential effects and what they can expect during the session.
- The Session: During the session, patients are given a regulated dosage of the substance in a comfortable, distraction-free environment to promote relaxation and self-reflection. The therapist remains present, offering continuous support and guidance.
- Integration Therapy Post-Session: This therapeutic procedure helps patients in deciphering and assimilating their experiences. Future sessions provide ongoing support and counselling to reinforce the insights and transformations gained during therapy.
How does psilocybin affect the brains of distressed patients?
Psilocybin interacts with the brain by attaching to serotonin receptors, primarily the 5-HT2A receptor. This interaction can cause alterations in perception, mood, and cognition, leading to significant consciousness shifts, emotional revelations, and novel perspectives.
Is psilocybin therapy available to everyone?
Not everyone is suitable for psilocybin therapy. Patients with specific mental health conditions or existential distress are extensively screened to exclude those with a history of psychosis.
Related Reads:
